Table 1.

Characteristics and comorbidities of participants vaccinated with BCG or placebo

Demographics and comorbidities	BCG (n = 183)	Placebo (n = 195)	p‐Value
Age (mean ± SD)	39.8 ± 14.0	41.6 ± 12.3	0.12
BMI (mean ± SD)	28.3 ± 15.3	28.2 ± 13.8	0.91
Female gender, no. (%)	105 (57.4)	123 (63.1)	0.29
Presence of old BCG scar, no. (%)	173 (94.5)	182 (93.3)	0.67
Physically active, no. (%)	100 (54.6)	98 (50.3)	0.41
Tobacco smoking, no. (%)	15 (8.2)	15 (7.7)	1
Regular alcohol drinking, no. (%)	80 (43.7)	93 (47.7)	0.47
Diabetes, no. (%)	10 (5.5)	12 (6.2)	0.82
Hypertension, no. (%)	32 (17.5)	34 (17.4)	1
Obesity, no. (%)	15 (8.2)	15 (7.7)	1
Chronic heart disease, no. (%)	4 (2.2)	1 (0.5)	0.202
Chronic kidney disease, no. (%)	0	0	‐
Chronic pulmonary disease, no. (%)	12 (6.6)	4 (2.1)	0.039
Chronic sinusitis, no. (%)	27 (14.8)	26 (13.3)	0.76
Respiratory allergies, no. (%)	24 (13.1)	23 (11.8)	0.75
Hemoglobinopathies, no. (%)	1	0	‐
Autoimmune disease, no. (%)	0	0	‐
Others, no. (%)	55 (30.1)	64 (32.8)	0.58
Symptomatology
Days symptomatic on admission (mean ± SD)	12.8 ± 15.3	13.2 ± 12.3	0.27
Cough, no. (%)	65 (35.5)	54 (27.7)	0.12
Fever, no. (%)	3 (1.6)	1 (0.5)	0.35
Fatigue, no. (%)	56 (30.6)	66 (33.8)	0.51
Coryza, no. (%)	18 (9.8)	13 (6.7)	0.35
Nasal congestion, no. (%)	29 (15.8)	29 (14.9)	0.88
Myalgia, no. (%)	27 (14.8)	34 (17.4)	0.49
Arthralgia, no. (%)	16 (8.7)	22 (6.2)	0.43
Headache, no. (%)	41 (22.4)	41 (21.0)	0.80
Sore throat, no. (%)	21 (11.5)	26 (13.3)	0.64
Anosmia, no. (%)	83 (45.5)	87 (44.6)	0.92
Ageusia, no. (%)	70 (38.3)	69 (35.4)	0.59
Nausea, no. (%)	15 (8.2)	16 (8.2)	1
Vomiting, no. (%)	1 (0.5)	1 (0.5)	‐
Diarrhea, no. (%)	14 (7.7)	10 (5.1)	0.40
Dyspnea, no. (%)	24 (13.1)	17 (8.7)	0.19
Asymptomatic, no. (%)	38 (20.8)	38 (19.5)	0.80

Note: Wilcoxon rank‐sum test with continuity correction.

Abbreviations: BCG, Bacillus Calmette‐Guérin; BMI, body mass index; no., number; SD, standard deviation.